EVA DE
LAGO FEMIA
Profesora titular de universidad
Publicacions (48) Publicacions de EVA DE LAGO FEMIA
2024
-
Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice
Biomedicine and Pharmacotherapy, Vol. 174
2023
-
Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice
Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108
2022
-
Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations
International Journal of Molecular Sciences, Vol. 23, Núm. 20
-
New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Biomolecules, Vol. 12, Núm. 9
-
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy
Journal of Medicinal Chemistry, Vol. 65, Núm. 2, pp. 1585-1607
2021
-
Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis
International Journal of Molecular Sciences, Vol. 22, Núm. 22
-
Chapter 2: Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System
RSC Drug Discovery Series (Royal Society of Chemistry), pp. 10-47
-
Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis
Brain Pathology, Vol. 31, Núm. 6
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
-
Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis
British Journal of Pharmacology
-
Retinal ganglion cell loss and microglial activation in a sod1g93a mouse model of amyotrophic lateral sclerosis
International Journal of Molecular Sciences, Vol. 22, Núm. 4, pp. 1-20
-
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis
European Journal of Medicinal Chemistry, Vol. 210
-
Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis
British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387
-
Tideglusib, a non-atp competitive inhibitor of gsk-3as a drug candidate for the treatment of amyotrophic lateral sclerosis
International Journal of Molecular Sciences, Vol. 22, Núm. 16
2020
-
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment
Scientific Reports, Vol. 10, Núm. 1
-
Pharmacokinetics of sativex® in dogs: Towards a potential cannabinoid-based therapy for canine disorders
Biomolecules, Vol. 10, Núm. 2
2019
-
Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
British Journal of Pharmacology, Vol. 176, Núm. 10, pp. 1585-1600
2018
-
Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 19, Núm. 5-6, pp. 377-386
-
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
Biochemical Pharmacology, Vol. 157, pp. 217-226
2017
-
Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis
DMM Disease Models and Mechanisms, Vol. 10, Núm. 5, pp. 551-558